# PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

- Link: https://www.thailand-business-news.com/pr-news/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026
- Published: 2026-11-20T19:00:00+07:00
- Author: PR Newswire

|   |

_– No dose-limiting toxicities observed across doses from 10 to 750 mg, with no 
PT0253-specific pre-treatment prophylaxis required –_

_– Monotherapy antitumor activity observed in colorectal and pancreatic cancers,
including a partial response in a patient previously treated with a KRAS-targeted
agent and disease control in 50% of patients who had progressed on prior (K)RAS-
targeted therapy –_

_– Promising combination activity observed in first-line metastatic pancreatic cancer,
with objective responses in 6 of 7 patients with at least two scans –_

BURLINGTON, Mass., Nov. 20, 2026 /PRNewswire/ — PAQ Therapeutics, a clinical-stage
biotechnology company focused on advancing targeted protein degradation to address
the unmet medical needs of patients with KRAS-driven cancers, today announced first
clinical data from its ongoing Phase 1 trial of PT0253 (NCT06797336). Alexander 
I. Spira, M.D., Ph.D., FACP, FASCO, of NEXT Oncology Virginia, presented the data
in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain.

The initial clinical findings demonstrate a differentiated safety profile for PT0253,
encouraging monotherapy antitumor activity, including in patients previously treated
with (K)RAS-targeted therapies, and promising early combination activity with standard-
of-care chemotherapy in first-line metastatic pancreatic cancer. These findings 
support the potential of KRAS degradation to address resistance mechanisms that 
may limit KRAS inhibitors, while offering a differentiated approach to sustained
KRAS target suppression and improved safety profile.

**Monotherapy Dose Escalation**

As of October 23, 2026, 44 patients with KRAS G12D-mutant advanced solid tumors 
had received weekly intravenous PT0253 at doses ranging from 10 to 750 mg. Patients
had received a median of 2.5 prior therapies, and 27% had received prior (K)RAS-
targeted therapy.

**Safety:** No dose-limiting toxicities (DLTs) were observed across the full dose
range of 10 to 750 mg. At doses of 120 to 750 mg (n=27), treatment-related adverse
events (TRAEs) were predominantly Grade 1–2. One patient (4%) experienced a Grade
≥3 TRAE. There were no serious TRAEs or discontinuations due to TRAEs. No PT0253-
specific pre-treatment prophylaxis was required.

**Antitumor activity:** PT0253 monotherapy demonstrated antitumor activity across
dose levels, with partial responses (PRs) observed at doses of 120 mg and above 
in patients with colorectal, pancreatic and lung cancers.

 ◦ **Colorectal cancer:** At doses of 120 mg and above, 3 of 6 patients with refractory
   colorectal cancer achieved partial responses (PRs, unconfirmed), including one
   patient whose disease had progressed on a prior (K)RAS-targeted agent. These 
   findings are encouraging in the context of the hypothesis that catalytic degradation
   of KRAS G12D may address EGFR-mediated feedback reactivation associated with 
   KRAS inhibition.
 ◦ **Pancreatic cancer:** At doses of 120 mg and above, 3 of 10 (K)RAS therapy-naïve
   patients had confirmed PRs, with most responses deepening over time. Nine of 
   10 patients achieved disease control.
 ◦ **Following prior (K)RAS-targeted therapy:** Among 12 patients whose disease 
   had progressed on prior (K)RAS-targeted therapy, 6 (50%) achieved disease control,
   demonstrating encouraging early activity in this difficult-to-treat population.

**First-Line Metastatic Pancreatic Cancer: PT0253 + mFOLFIRINOX**

Fourteen patients received PT0253 350 mg once weekly in combination with modified
FOLFIRINOX (mFOLFIRINOX), a standard-of-care chemotherapy regimen, and 13 remained
on treatment as of the October 23, 2026 data cutoff.

Among the 7 patients with at least two scans, 6 achieved objective responses: one
confirmed complete response (CR) and five PRs, four of which were confirmed.

The combination was generally well tolerated, with a safety profile consistent with
mFOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific prophylaxis.
Median relative dose intensity was 91% for PT0253, while mFOLFIRINOX dose intensity
was 75–80% across components, consistent with the expected range for this chemotherapy
regimen.

These early findings support further investigation of PT0253 in combination with
standard-of-care chemotherapy in first-line pancreatic cancer.

"We are encouraged by these initial clinical data for PT0253. Its differentiated
safety profile, monotherapy antitumor activity and promising early combination results
support our strategy of advancing KRAS protein degradation as a new therapeutic 
approach," said Nan Ji, Ph.D., Chief Executive Officer of PAQ Therapeutics. "We 
look forward to further evaluating PT0253 in pancreatic and colorectal cancer expansion
cohorts."

"PT0253 as a monotherapy was well tolerated across the full dose range without pre-
treatment prophylaxis. Importantly, in combination with mFOLFIRINOX in first-line
pancreatic cancer, patients received chemotherapy at its expected relative dose 
intensity," said Andrew P. Krivoshik, M.D., Chief Medical Officer of PAQ Therapeutics."
With no dose-limiting toxicities and a high rate of deep responses, the first-line
combination data are an important demonstration of combinability with standard-of-
care therapy."

"Patients with KRAS G12D-mutant cancers who progress on chemotherapy, and increasingly
on KRAS-targeted therapies, have few options," said Dr. Spira. "It is encouraging
to see antitumor activity, including a partial response and disease control, in 
patients whose disease had progressed on prior (K)RAS-targeted therapy. The favorable
tolerability observed across the dose range and in combination with standard-of-
care chemotherapy is also encouraging. The expansion cohorts will be important to
further evaluate these early findings."

**About PT0253**

PT0253 is an investigational, intravenously administered small-molecule degrader
that selectively eliminates the KRAS G12D mutant protein. It is designed to address
resistance mechanisms observed with (K)RAS inhibitors, provide sustained KRAS target
suppression, and improve safety profile.

The Phase 1 clinical trial of PT0253 is designed to evaluate safety and tolerability,
and to determine the maximally tolerated dose and/or recommended Phase 2 dose of
PT0253 in adult patients with KRAS G12D-mutant advanced solid tumors.

**About PAQ Therapeutics**

PAQ Therapeutics is a clinical-stage biotechnology company focused on advancing 
targeted protein degradation to address the unmet medical needs of patients with
KRAS-driven cancers. PAQ’s clinical pipeline comprises PT0253, a selective KRAS 
G12D degrader, and PT0511, a pan-KRAS degrader, both in Phase 1 development for 
patients with advanced solid tumors. The company is based in Burlington, Massachusetts.

**Forward-Looking Statements**

This press release contains forward-looking statements regarding the development
and potential of PT0253 and the timing of future data. Preliminary data may change
as more patient data become available, and early results may not predict later trial
results. PAQ undertakes no obligation to update these statements except as required
by law.

_Data qualification: Clinical data are preliminary and subject to ongoing data monitoring._

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026 ](https://en.prnasia.com/story/archive/5098194_CN98194_0?rand=184833)
